Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 3, 2009, Pages 249-258

  Nebbioso, Marcella ^a   Grenga, Roberto ^a   Karavitis, Panagiotis ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

ARTICLE; CLINICAL EVALUATION; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EYE DISEASE; EYE EXAMINATION; HUMAN; MULTIFOCAL ELECTORETINOGRAPHY; RETINA MACULA LUTEA; RETINOPATHY;

ANTIMALARIALS; CHLOROQUINE; EARLY DIAGNOSIS; ELECTRORETINOGRAPHY; HUMANS; HYDROXYCHLOROQUINE; MALARIA; RETINAL DISEASES;

EID: 66249094540     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0106     Document Type: Article

References (42)

1. Carr, R.E., Gouras, P., and Gunkel, R.D. Chloroquine therapy. Early detection by retinal threshold test. Arch Ophthalmol. 75:171-178, 1966.
2. Fishman, G.A. Toxic retinopathies. Contemp. Ophthalmol. 1:1-5, 1980.
3. Tobin, R., Krobel, G.B., and Ryners, R.I. Hydroxychloroquine: Seven years experience. Arch Ophthalmol. 100:81-83, 1982.
4. Rigaudiere, F., Pizzato, M., Albuisson, E., et al. Statistical results of 700 electrophysiologic tests (ERG) in patients without ophthalmologic manifestations treated with synthetic antimalarials for rheumatologic or dermatologic disease. Ophthalmologie. 4:254-259, 1990.
5. Weiner, A., Sandberg, M.A., Gaudio, A.R., et al. Hydroxychloroquine retinopathy. Am. J. Ophthalmol. 112:528-534, 1991.
6. Falcone, P.M., Paolini, L., and Lou, P.L. Hydroxychloroquine toxicity despite normal dose therapy. Ann. Ophthalmol. 25:385-388, 1993.
7. Infante, I., Martin, A.D., and Heckenlively, R.J. Hydroxychloroquine and retinal toxicity. In: Kolder HEJW (ed.), 20th ISCEV Symposium, Iowa City, Iowa, USA. Doc Ophthalmol Proc Series. (37):121-126, 1983.
8. Shroyer, N.F., Lewis, R.A., and Lupski, J.R. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy. Am. J. Ophthalmol. 131:761-766, 2001.
9. Maturi, R.K., Folk, J.C., Nichols, B., et al. Hydroxychloroquine retinopathy. Arch Ophthalmol. 117:1262-1263, 1999.
10. Marmor, M.F. The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am. J. Ophthalmol. 140:894-895, 2005.
11. Maturi, R.K., Yu, M., and Weleber, R.G. Multifocal Electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 122:973-981, 2004.
12. Tzekov, R. Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. Doc. Ophthalmol. 110:111-120, 20 05.
13. Ingster-Moati, I., Crochet, M., Manchon, E., et al. Surveillance ophtalmologique des patients sous APS au long cours: analyse d'une population de 925 patients. J. Fr. Ophtalmol. 27:367-373, 2004.
14. Fishman, G.A. The electroretinogram, the electro-oculogram. Electrophysiologic testing. In: Fishman, G., Birch, D.G., Holder, G.E., et al., eds. Electrophysiologic testing in Disorders of the Retina, Optic Nerve, and Visual Pathway. The foundation of the American Academy of Ophthalmology-San Francisco. Singapore: Leo, 2001:88-90, 167.
15. Mehta, D. British National Formulary 53 Pharmaceutical Press 3/2007: 298, 481-2 BMJ Publishing Group Ltd, BMA House Tavistock Square, London, WC1H 9JP, UK RPS Publishing, Royal Pharmaceutical Society of Great Britain, 1 Lambeth High Street, London, SEI 7 JN, UK.
16. Duncker, G., and Bredehorn, T. Chloroquine-induced lipidosis in the rat retina: functional and morphological changes after withdrawal of the drug. Graefes Arch. Clin. Exp. Ophthalmol. 234:378-381, 1996.
17. Tanenbaum, L., and Tuffanelli, D.L. Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine. Arch. Dermatol. 116:587-591, 1980.
18. Wetterholm, D.F., and Winter, F.C. Histopathology of chloroquine retinal toxicity. Arch. Ophthalmol. 71:82-87, 1964.
19. Ramsey, M.S., and Fine, B.S. Chloroquine toxicity in the human eye. Histopathologic observations by electron microscopy. Am. J. Ophthalmol. 73:229-235, 1972.
20. Rosenthal, A.R., Kolb, H., Bergsma, D., et al. Chloroquine retinopathy in the rhesus monkey. Invest. Ophthalmol. Vis. Sci. 17:1158-1175, 1978.
21. Rynes, R.I. Antimalarial drugs in the treatment of rheumatological diseases. Br. J. Rheumatol. 36:799-805, 1997.
22. Rynes, R.I. Antimalarials. In: Dixon, J.S., Furst, D.E., eds. Secondline Agents in the Treatment of Rheumatic Diseases. New York: Marcel Dekker Inc., 1992:245-266.
23. Easterbrook, M. Detection and prevention of maculopathy associated with antimalarial agents. Int. Ophthalmol. Clin. 39:49-57, 1999.
24. Bernstein, H.N. Ocular safety of hydroxychloroquine sulfate (Plaquenil). Ann. Ophthalmol. 23:292-296, 1991.
25. Sutter, E.E., and Tran, D. The field topography of ERG components in man. The photopic luminance response. Vision Res. 32:433-466, 1992.
26. Moschos, M.N., Moschos, M.M., Apostolopoulos, M., et al. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc. Ophthalmol. 108:47-53, 2004.
27. Penrose, P.J., Tzekov, R.T., Sutter, E.E., et al. Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina. 23:503-512, 2003.
28. Marmor, M.F., Hood, D.C., Keating, D., et al. Guidelines for basic multifocal electroretinography (mfERG). Doc. Ophthalmol. 106:105 -115, 2003.
29. Hood, D.C., Bach, M., Brigell, M., et al. ISCEV guidelines for clinical multifocal electroretinography (2007 edition). Doc. Ophthalmol. 116:1-11, 2008.
30. Kellner, U., Kraus, H., and Foerster, M.H. Multifocal ERG in chloroquine retinopathy: regional variant retinal dysfunction. Graefes Arch. Clin. Exp. Ophthalmol. 238:94-97, 2000.
31. So, S.C., Hedges, T.R., Schuman, J.S., et al. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. Ophthal. Surg. Lasers Imaging. 34:251-258, 2003.
32. Tzekov, R.T., Serrato, A., and Marmor, M.F. ERG findings in patients using hydroxychloroquine. Doc. Ophthalmol. 108:87-97, 2004.
33. Marmor, M.F., Carr, R.E., Easterbrook, M., et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 109:1377-1382, 2002.
34. Lai, T.Y., Chan, W.M., Li, H., et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am. J. Ophthalmol. 140:794-807, 2005.
35. Lai, T.Y., Ngai, J.W., Chan, W.M., et al. Visual field and multi-focal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc. Ophthalmol. 112:177-187, 2006.
36. Lyons, J.S., and Severns, M.L. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am. J. Ophthalmol. 143:801-809, 2007.
37. Kellner, U., Kellner, S., and Weinitz, S. Chloroquine retinopathy: lipofuscin-and melanin-related fundus autof uorescence, optical coherence tomography and multifocal electroretinography. Doc. Ophthalmol. 116:119-127, 2008.
38. Mahon, G.J., Anderson, H.R., Gardiner, T.A., et al. Chloroquine causes lysosomal dysfunction in neural retina and RPE: implications for retinopathy. Curr. Eye Res. 28:277-284, 2004.
39. Liu, J., Lu, W., Reigada, D., et al. Restoration of lysosomal pH in RPE cells from cultured human and ABCA4(-/-) mice: pharmacologic approaches and functional recovery. Invest. Ophthalmol. Vis. Sci. 49:772-780, 2008.
40. Rüther, K., Foerster, J., Berndt, S., et al. Chloroquine/ hydroxychloroquine: variability of retinotoxic cumulative doses. Ophthalmologe. 104:875-879, 2007.
41. Hart, W.M., Jr, Burde, R.M., Johnston, G.P., et al. Static perimetry in chloroquine retinopathy. Perifoveal patterns of visual field depression. Arch. Ophthalmol. 102:377-380, 1984.
42. Hood, D.C., Frishman, L.J., Saszik, S., et al. Retinal origins of the primate multifocal ERG: implications for the human response. Inv. Ophthalmol. Vis. Sci. 43:1673-1685, 2002.